Crinetics Pharmaceuticals Files 8-K

Ticker: CRNX · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1658247

Crinetics Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCrinetics Pharmaceuticals, Inc. (CRNX)
Form Type8-K
Filed DateJan 14, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: filing, sec

Related Tickers: CRNX

TL;DR

CRNX filed an 8-K, likely standard disclosures. Watch for exhibit details.

AI Summary

On January 14, 2025, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the filing of financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates Crinetics Pharmaceuticals is providing updates and required documentation to the SEC, which is standard for public companies but may contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.

Key Players & Entities

  • Crinetics Pharmaceuticals, Inc. (company) — Registrant
  • January 14, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 26-3744114 (tax_id) — IRS Employer Identification No.
  • 6055 Lusk Boulevard, San Diego, California 92121 (address) — Principal Executive Offices
  • (858) 450-6464 (phone_number) — Registrant's Telephone Number

FAQ

What is the primary purpose of this 8-K filing for Crinetics Pharmaceuticals, Inc.?

The filing is primarily for Regulation FD Disclosure and the filing of Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' section.

On what date was this 8-K report filed or effective?

The report was filed as of January 14, 2025, and the date of the earliest event reported is also January 14, 2025.

In which state was Crinetics Pharmaceuticals, Inc. incorporated?

Crinetics Pharmaceuticals, Inc. was incorporated in Delaware.

What is the principal executive office address for Crinetics Pharmaceuticals, Inc.?

The principal executive offices are located at 6055 Lusk Boulevard, San Diego, California 92121.

Does the provided text detail any specific material events or financial results?

No, the provided text is an excerpt from the 8-K filing's header and does not detail specific material events or financial results.

Filing Stats: 1,151 words · 5 min read · ~4 pages · Grade level 13.5 · Accepted 2025-01-14 17:02:31

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 14, 2025 at 4:30 pm Pacific Time, Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the "Company," "Crinetics," "we," "us," or "our"), will present a Company update at the 43rd annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 13-16, 2025. A live audio webcast of Dr. Struthers' presentation may be accessed on the Events & Presentations section of the Company's website or directly on the J.P. Morgan virtual meeting platform. During the presentation, the Company will reference the corporate slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The presentation will feature an overview of Crinetics' key priorities and anticipated milestones for 2025. These include: The continued efforts to further increase commercial readiness so that the Company can rapidly provide patients in the United States with acromegaly with broad access to once-daily oral paltusotine if the new drug application is approved, with the Prescription Drug User Fee Act Target Action Date of September 25, 2025. The continued development of atumelnant, an investigational adrenocorticotropic hormone (ACTH) antagonist, for congenital adrenal hyperplasia (CAH) and Cushing's disease, with Phase 3 initiation for adult CAH patients expected in the first half of 2025 and later-stage trial initiations for pediatric CAH patients and patients with Cushing's disease expected in 2025. The continued advancement of Investigational New Drug-enabling studies of 4 development candidates for neuroendocrine tumors and somatostatin receptor type-2-expressing solid tumors, hyperparathyroidism, Graves' disease, thyroid eye disease, and autosomal dominant polycystic kidney disease. The Company's updated corporate presentation has been posted to the Company's website, www.crinetics.com. The Company plans to

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements, including statements regarding [statements regarding the NDA review process and the expected timing of the completion of the FDA's review of the NDA for paltusotine for the treatment or maintenance of treatment of acromegaly in the United States, the therapeutic potential and clinical benefits or safety profile of paltusotine for patients with acromegaly, the plans and timelines for the commercial launch paltusotine for acromegaly, if approved, and of our commercial readiness efforts, the clinical development of atumelnant, including the therapeutic potential and clinical benefits or safety profile thereof, the plans for and the therapeutic potential of our development candidates, and the potential of our other research, discovery, and clinical trial programs.] These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation, the risks and uncertainties described in the company's periodic filings with the SEC. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Slide Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: January 14, 2025 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.